Human MMP-9 activity in urine as measured by the QuickZyme MMP-9 activity assay was shown to be a strong independent prognostic marker of poor survival in bladder cancer.  Click here for more information

Human MMP-9 activity in urine as measured by the QuickZyme MMP-9 activity assay was shown to be a marker of renal dysfunctioning in patients with type2 diabetes mellitus.  Click here for more information

QuickZyme Biosciences launched a new human specific MMP-9 activity assay. The assay is a quantitative replacement for zymography. The sensitivity of the assay is unique: 5 pg/ml.  Click here for more information (more…)

QuickZyme Biosciences launched a new mouse specific MMP-9 activity assay. The assay is a quantitative replacement for zymography. The sensitivity of the assay is unique: 1 pg/ml. The assay is available via QuickZyme Biosciences. Click here for more information (more…)

Leiden, July 2 2009 – ProteoNic, the protein expression experts, announces it has entered into a license agreement with the research organization TNO. Last year the parties formalized their collaboration on improving the expression yields of mammalian host systems using the ProteoNic proprietary UNicTM toolbox. In the past year the UNic-MTeeTM (one of ProteoNic’s Translation Enhancement Element products) has proven successful in commercial production conditions using suspension CHO cells and serum free medium. TNO therefore, decided to obtain a commercial license for the production of modified pro-urokinase detection enzymes for use in its proprietary QuickZyme technology platform. The financial details of this deal were not disclosed.

ProteoNic’s UNicTM Toolbox offers services and proprietary technologies for enhancing protein expression by optimizing messenger RNA (mRNA). ProteoNic is one of very few companies in the world to address protein expression enhancement through mRNA optimization, instead of the standard DNA transcription methods. By applying ProteoNic’s technology, TNO has significantly increased its protein yield while reducing its production costs.

TNO Senior Investigator Jan Verheijen: “We are extremely happy to be able to implement the UNicTM technology in the production process of our QuickZyme pro- urokinase detection enzymes. This will not only lead to significant cost reductions, but also allows us to meet the requests of our customers within very short time frames”

Maurice van der Heijden, Research Manager and Head Mammalian Group at ProteoNic “We are very pleased to support TNO with our translation enhancement technology. TNO convincingly showed that UNicTM and QuickZyme Technologies are fully compatible. Our UNic-MTeeTM product has been developed to be widely applicable in mammalian expression platforms. This license confirms that important yield increases can be obtained in the commercial production of enzymaltically active human proteins. “About TNO

TNO is a prominent, independent research and technology organization, whose expertise and research contributes significantly to the competitiveness of businesses and organizations, to the economy and to the quality of life as a whole. Its versatility and capacity to apply this knowledge makes TNO unique. TNO employs about 4.300 professionals. TNO operates in five core areas: TNO Quality of Life, TNO Defense, Security and Safety, TNO Science and Industry, TNO Built Environment and Geosciences, TNO Information and Communication Technology. www.tno.nl

About ProteoNic ProteoNic, located in the Netherlands, offers specialized products and services in the field of improving protein expression. As one of the very few companies in the world, ProteoNic provides leading expertise in optimizing the translation of messenger RNA (mRNA). Services include construct design and cloning, transformation, and high-throughput screening of commercial protein production hosts.

Over the coming years, ProteoNic aims to establish its UNicTM technology as the state-of-the-art, industry standard within protein-based industries. ProteoNic’s activities focus on industry-relevant fungal, yeast, plant and mammalian expression hosts, for which it has developed platform- specific products and services. Its technology leads to significantly higher yields and greater manufacturing flexibility with lower production costs. www.proteonic.nl